California 2021-2022 Regular Session

California Senate Bill SB473

Introduced
2/17/21  
Introduced
2/17/21  
Refer
2/25/21  
Refer
2/25/21  
Refer
3/10/21  
Refer
3/10/21  
Refer
1/3/22  
Refer
1/3/22  
Report Pass
1/12/22  
Refer
1/13/22  
Refer
1/13/22  
Engrossed
1/24/22  
Refer
5/5/22  
Refer
5/5/22  
Report Pass
6/15/22  
Report Pass
6/15/22  
Refer
6/16/22  

Caption

Health care coverage: insulin cost sharing.

Impact

The bill's provisions amend existing health care regulations under the Knox-Keene Health Care Service Plan Act and related insurance codes. It specifically aims to improve access to insulin treatments, which have seen substantial price increases over recent years. This legislation is expected to significantly reduce out-of-pocket costs for consumers who rely on insulin for diabetes management, potentially leading to better health outcomes and reduced complications related to diabetes due to improved adherence to treatment plans.

Summary

Senate Bill 473, introduced by Senator Bates, focuses on enhancing health care coverage related to insulin and its management in California. It seeks to prohibit health care service plans and insurance policies from imposing any cost-sharing requirements on covered insulin prescriptions starting January 1, 2023. The bill mandates that patients pay a maximum copayment of $35 per month for each dosage form of insulin prescribed, regardless of the type. Additionally, it prohibits deductibles on benefits related to diabetes management, aiming to alleviate financial burdens faced by those living with diabetes.

Sentiment

The sentiment surrounding SB 473 is generally positive among supporters, who view it as a crucial step towards ensuring equitable access to life-saving medications. Advocates argue that by capping insulin costs and eliminating deductibles, this bill will lead to enhanced financial security and health outcomes for individuals with diabetes. However, some stakeholders may express concerns regarding potential impacts on insurance providers and the broader health care market, particularly in terms of cost management and sustainability.

Contention

Notable points of contention revolve around the balance between cost control and access to necessary medications. While the intent is to improve access to insulin, there are concerns from insurers about the implications of removing cost-sharing and premiums for such coverage. Stakeholders may debate how these changes will affect premiums for other policyholders and the overall funding of health care plans, especially in high deductible health plans. The discussions are ongoing as the bill moves through the legislative process.

Companion Bills

No companion bills found.

Similar Bills

CA SB90

Health care coverage: insulin affordability.

CA SB40

Health care coverage: insulin.

CA AB2203

Insulin cost-sharing cap.

CA AB97

Health care coverage: insulin affordability.

CA SB306

Sexually transmitted disease: testing.